PROLIA 60

Prolia 60mg Injection, containing the active ingredient Denosumab, is a medication primarily used for the treatment of osteoporosis, a condition characterized by weakened and fragile bones. It is also prescribed to help prevent bone complications in patients with certain types of cancer, such as multiple myeloma and those with bone metastases. The way Prolia 60mg Injection works is by inhibiting a protein called RANK ligand. This protein plays a crucial role in the process of bone tissue breakdown. By blocking RANK ligand, the injection effectively slows down bone resorption, thereby helping to strengthen bones.

Clinical studies have demonstrated that Prolia 60mg Injection can significantly increase bone density, which in turn reduces the risk of fractures. This benefit has been observed in postmenopausal women with osteoporosis and in patients experiencing bone loss due to cancer. For individuals with moderate renal impairment, close monitoring of kidney function may be necessary during treatment to ensure its safe and effective use. Prolia 60mg Injection is also used to treat osteoporosis in both postmenopausal women and men who are at high risk of fractures.

It is important to note certain contraindications and precautions for Prolia 60mg Injection. It should not be used in individuals with known hypersensitivity or allergic reactions to any of its components. Adequate supplementation with both calcium and vitamin D is essential throughout the treatment period. Prolia 60mg Injection is not approved for use in children and adolescents, as its safety and effectiveness in pediatric populations have not been established; therefore, its use is contraindicated in individuals under 18 years of age. This medication should also be used with caution in individuals with pre-existing hypoparathyroidism, a condition characterized by low parathyroid hormone levels.